Inside Precision Medicine October 18, 2024
Innovative research from the University of Ottawa suggests that edaravone, a drug currently used to treat amyotrophic lateral sclerosis (ALS), could be repurposed to fight glioblastoma, an aggressive and often incurable brain tumor. Published in Stem Cell Reports, the study demonstrates that edaravone targets brain tumor stem cells (BTSCs), the highly resistant cells responsible for tumor growth and recurrence, offering a new approach in the battle against these lethal grade 4 brain tumors.
Led by Arezu Jahani-Asl, PhD, Canada Research Chair in Neurobiology of Disease at the University of Ottawa, the team found that edaravone inhibits the self-renewal and proliferation of BTSCs, which are at the core of glioblastoma’s resistance to current therapies. These findings are particularly promising because glioblastoma...
Today's Sponsors
Today's Sponsor